Terms: = Kidney tumors AND PDGFB, SIS, 5155, ENSG00000100311, FLJ12858, PDGF2, P01127, c-sis, SSV AND Treatment
8 results:
1. A Novel Cuproptosis-Related Prognostic Gene Signature and Validation of Differential Expression in Clear Cell Renal Cell Carcinoma.
Bian Z; Fan R; Xie L
Genes (Basel); 2022 May; 13(5):. PubMed ID: 35627236
[TBL] [Abstract] [Full Text] [Related]
2. BAI1 as a Prognostic Marker of Clear Cell Renal Cell Carcinoma (ccRCC).
Pesta M; Travnicek I; Kulda V; Windrichova J; Rezackova H; Houfkova K; Macanova T; Bendova B; Nestorova A; Hes O; Hora M; Topolcan O; Polivka J
Anticancer Res; 2021 Sep; 41(9):4463-4470. PubMed ID: 34475070
[TBL] [Abstract] [Full Text] [Related]
3. Gold Nanorods are Selective Cytotoxic Agents.
El Gendy M; Weinfeld M; Abdoon A
Anticancer Agents Med Chem; 2022; 22(5):991-998. PubMed ID: 34315395
[TBL] [Abstract] [Full Text] [Related]
4. Suppressive effects of iron chelation in clear cell renal cell carcinoma and their dependency on VHL inactivation.
Greene CJ; Sharma NJ; Fiorica PN; Forrester E; Smith GJ; Gross KW; Kauffman EC
Free Radic Biol Med; 2019 Mar; 133():295-309. PubMed ID: 30553971
[TBL] [Abstract] [Full Text] [Related]
5. Predictive Immunohistochemical Markers Related to Drug Selection for Patients Treated with Sunitinib or Sorafenib for Metastatic Renal Cell Cancer.
Ma X; Wang L; Li H; Zhang Y; Gao Y; Guo G; Liu K; Meng Q; Zhao C; Wang D; Song Z; Zhang X
Sci Rep; 2016 Aug; 6():30886. PubMed ID: 27488093
[TBL] [Abstract] [Full Text] [Related]
6. [The use of Surgisis® optimizes and simplifies partial nephrectomy for large renal tumors].
Schnoeller TJ; de Petriconi R; Hefty R; Jentzmik F; Al Ghazal A; Steinestel J; Mueller J; Zengerling F; Schrader M; Schrader AJ
Urologe A; 2013 Feb; 52(2):246-51. PubMed ID: 23178845
[TBL] [Abstract] [Full Text] [Related]
7. Noninvasive contrast-enhanced US quantitative assessment of tumor microcirculation in a murine model: effect of discontinuing anti-VEGF therapy.
Guibal A; Taillade L; Mulé S; Comperat E; Badachi Y; Golmard JL; Le Guillou-Buffello D; Rixe O; Bridal SL; Lucidarme O
Radiology; 2010 Feb; 254(2):420-9. PubMed ID: 20093514
[TBL] [Abstract] [Full Text] [Related]
8. Cost analysis of open, laparoscopic, and percutaneous treatment options for nephron-sparing surgery.
Link RE; Permpongkosol S; Gupta A; Jarrett TW; Solomon SB; Kavoussi LR
J Endourol; 2006 Oct; 20(10):782-9. PubMed ID: 17094755
[TBL] [Abstract] [Full Text] [Related]
